Chinese scholars have identified a medium antibody that prevents the new coronavirus from invading

may 14, the results of a new coronavirus antibody study, jointly completed by Chinese scholars, were published online in the journal Science. The researchers found two human-specific antibodies that prevent the new coronavirus S protein-binding domain RBD from binding to the human cell-like ACE2.
so far, there are no specific drugs or vaccines for the new coronavirus. Currently, most treatments are aimed at the "key" of the new coronavirus's invasion of humans, the S protein. S protein-mediated virus and host cells bind and invade, it consists of S1, S2 domain two parts, respectively, mediated subject binding and membrane fusion. The subject binding domain (RBD) is located in S1. The new study suggests that screening anti-neocovirus mesobacterial antibodies by using RBD proteins is a priority strategy that can be used at this time.
A team of researchers from Capital Medical University,
Beijing Institute of Life Sciences,
Institute of Microbiology,
Tianjin Industrial Biotechnology Research Institute, Shenzhen Third People's Hospital, China Center for Disease Control and Prevention, etc., isolated four human-sourced monoclonal antibodies (B5, B38, H2 and H4) from a recovered patient, all of which showed meso-ability in-body.
studies have shown that all four antibodies can bind to RBD, with B38 and H4 competing perfectly with ACE2. In contrast, B5 shows partial competition, while H2 does not compete with ACE2, indicating that these antibodies use different meso-coordination mechanisms. Further experiments have shown that although both B38 and H4 compete perfectly with ACE2, both antibodies identify different parts of RBD.
analysis of the structure of B38 and RBD, it is clear that the binding points of antibodies and RBDs have a significantly similarity to the binding points of human cells ACE2 and RBD. Wu Yan, the paper's first author and author of the communication, explained in an interview with China Science Daily that "the equivalent of 'occupying' the binding point between RBD and ACE2, the virus can no longer bind ACE2." One
highlight of this study is that "cocktail antibody therapy", which mixes B38 and H4 antibodies, has a stronger mesoactive effect on the virus. Therefore, this approach may be considered as an alternative treatment strategy to avoid potential escape mutations. The authors say the identified meso-antibodies are expected to be a candidate for the treatment of the new coronavirus.
In fact, the original plasma therapy used in the outbreak of the new crown is to isolate the plasma of recovering patients, after treatment, to patients with severe or critical illness, which works by the antibodies in the plasma, containing high-level antibodies, especially meso-antibodies to play an antiviral role. Wu Yan pointed out, however, that plasma therapy has a certain risk, with a moderate activity of high-purity monoclonal antibodies as a drug more stable and reliable.
, monoclonal antibodies as antiviral drugs in AIDS, Ebola haemorrhagic fever and other diseases in the treatment has achieved good results. At present, the research team is working with domestic companies to develop related antibodies, but they go to clinical need a series of strict drug safety trials, quality control, and finally to promote.
Wu Yan and
Fellow Gao Fu,
Tianjin Institute of Industrial Biotechnology Associate Researcher Peak and Liu Lei, President of the Third People's Hospital of Shenzhen, are co-authors of the paper. (Source: Feng Lifei, China Science Journal)
relevant paper information: